The Molecular Mechanism of Action of the Antiresorptive and Antiinflammatory Drug Clodronate: Evidence for the Formation in Vivo of a Metabolite That Inhibits Bone Resorption and Causes Osteoclast and Macrophage Apoptosis

Arthritis and Rheumatism

Volumn 44, Issue 9, 2001, Pages 2201-2210

  Frith, Julie C ^a   Mönkkönen, Jukka ^b   Auriola, Seppo ^b   Mönkkönen, Hannu ^b   Rogers, Michael J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE 5' O (BETA,GAMMA DICHLOROMETHANE)TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENOSINE-5'-O-(BETA,GAMMA-DICHLOROMETHANE)TRIPHOSPHATE; ALENDRONIC ACID; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; CLODRONIC ACID; DRUG DERIVATIVE; LIPOSOME; RAP1 PROTEIN;

ANIMAL; APOPTOSIS; ARTICLE; CELL CULTURE; CYTOLOGY; DRUG EFFECT; METABOLISM; MICROCAPSULE; OSTEOCLAST; OSTEOLYSIS; PATHOLOGY; PERITONEUM MACROPHAGE; PROTEIN PROCESSING; RABBIT; RAT; SPRAGUE DAWLEY RAT;

ADENOSINE TRIPHOSPHATE; ALENDRONATE; ANALGESICS, NON-NARCOTIC; ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BONE RESORPTION; CAPSULES; CELLS, CULTURED; CLODRONIC ACID; LIPOSOMES; MACROPHAGES, PERITONEAL; OSTEOCLASTS; PROTEIN ISOPRENYLATION; RABBITS; RAP1 GTP-BINDING PROTEINS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0035460134     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200109)44:9<2201::AID-ART374>3.0.CO;2-E     Document Type: Article

References (40)

1. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkoncn J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-78.
2. Adachi JD, Olszynski WP, Hanley DA, Hodsman AB, Kendler DL, Siminoski KG, et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 2000;29:228-51.
3. Meunier PJ, Delmas PD, Eastell R, McClung MR, Papapoulos S, Rizzoli R, et al. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clin Ther 1999;21: 1025-44.
4. Siris ES. Goals of treatment for Paget's disease of hone. J Bone Miner Res 1999;14 Suppl 2:49-52.
5. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action: alendronate localization in rat hone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88:2095-105.
6. Ebetino FH, Francis MD, Rogers MJ, Russell RGG. Mechanisms of action of etidronate and other hisphosphonates. Rev Contemp Pharmacother 1998;9:233-43.
7. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994;174:83-93.
8. Oldenhorg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science 2000;288:2051-4.
9. Monkkonen J, Liukkonen J, Taskinen M, Heath TD, Urtti A. Studies on liposome formulations for intra-articular delivery of clodronate. J Controlled Release 1995;35:145-54.
10. Camilleri JP, Williams AS, Amos N, Douglas-Jones AG, Love WG, Williams BD. The effect of free and liposome-encapsulated clodronate on the hepatic mononuclear phagocyte system in the rat. Clin Exp Immunol 1995;99:269-75.
11. Kinne RW, Schmidt-Weher CB, Hoppe R, Buchner E, Palombo-Kinne E, Nurnberg E, et al. Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Arthritis Rheum 1995;38: 1777-90.
12. Van Lent PL, van den Bersselaar L, van den Hoek AE, van de Ende M, Dijkstra CD, van Rooijen N, et al. Reversible depletion of synovial lining cells after intra-articular treatment with liposome-encapsulated dichloromethylene diphosphonate. Rheumatol Int 1993;13:21-30.
13. Barrera P, Blom A, van Lent PLEM, van Bloois L, Beijnen JH, van Rooijen N, et al. Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum 2000;43:1951-9.
14. Monkkonen J, Pennanen N, Lapinjoki S, Urtti A. Clodronate (diehloromethylene bisphosphonate) inhibits LPS-stimulated IL-6 and TNF production by RAW 264 cells. Life Sci 1994;54: PL229-34.
15. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000;373:231-41.
16. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, hone resorption and kinase activation in vitro. Proc Natl Acad Sci USA 1999;96:133-8.
17. Coxon FP, Helfrich MH, van 't Hof RJ, Sebti SM, Ralston SH, Hamilton AD. et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000;15:1467-76.
18. Hiroi-Furuya E, Kameda T, Hiura K, Mano H, Miyazawa K, Nakamaru Y, et al. Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolatemature osteoclasts. Calcif Tissue Int 1999;64:219-23.
19. Frith JC, Monkkonen J, Blackburn GM, Russell RG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997;12:1358-67.
20. Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999;56:131-40.
21. Blackburn GM, Kent DE, Kolkmann F. The synthesis and metal binding characteristics of novel, isopolar phosphonate analogues of nucleotides. J Chem Soc Perkin Trans 2000;1:1118-22.
22. Monkkonen J, Taskinen M, Auriola SO, Urtti A. Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro. J Drug Target 1994;2:299-308.
23. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-87.
24. Nesbitt S, Nesbit A, Helfrich M, Horton M. Biochemical characterization of human osteoclast integrins: osteoclasts express alpha v beta 3, alpha 2 beta 1, and alpha v beta 1 integrins. J Biol Chem 1993;268:16737-45.
25. Monkkonen H, Moilanen P, Monkkonen J, Frith JC, Rogers MJ, Auriola S. Analysis of an adenine nucleotide-containing metabolite of clodronate using ion pair high-performance liquid chromatography-electrospray ionisation mass spectrometry. J Chromatogr B Biomed Sci Appl 2000;738:395-403.
26. Van't Hof RJ, Tuinenburg-Bol RA, Nijweide PJ. Induction of osteoclast characteristics in cultured avian blood monocytes: modulation by osteoblasts and 1,25-(OH)2 vitamin D3. Int J Exp Pathol 1995;76:205-14.
27. Reszka AA, Halasy-Nagy J, Rodan GA. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001;59:193-202.
28. Plosker GL, Goa KL. Clodronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1994;47:945-82.
29. Rogers MJ, Brown RJ, Hodkin V, Blackburn GM, Russell RGG, Watts DJ. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun 1996;224:863-9.
30. Dunford JE, Thompson K, Coxon FP, Luckman SP. Hahn FM, Poulter CD, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-42.
31. Van Beek E, Lowik C, van der Pluijm G, Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999;14:722-9.
32. Masarachia P, Weinreb M, Balena R, Rodan GA. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996;19:281-90.
33. Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, et al. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 1995;16:235-45.
34. Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 1991;49:407-15.
35. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S. Nakamura I, et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995;17:137-44.
36. Schmidt-Weber CB, Rittig M, Buchner E, Hauser I, Schmidt I, Palombo-Kinne E. et al. Apoptotic cell death in activated monocytes following incorporation of clodronate-liposomes. J Leukoc Biol 1996;60:230-44.
37. Naito M, Nagai H, Kawano S, Umezu H, Zhu H, Moriyama H, et al. Liposome-encapsulated dichloromethylene diphosphonate induces macrophage apoptosis in vivo and in vitro. J Leukoc Biol 1996;60:337-44.
38. Coxon FP, Benford HL, Russell RGG, Rogers MJ. Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol Pharmacol 1998;54: 631-8.
39. Halasy JM, Rodan GA, Reszka AA. Relationship of alendronate effects to osteoclast apoptosis [abstract]. Bone 1998;23 Suppl: S552.
40. Huitinga I, van Rooijen N, de Groot CJ, Uitdehaag BM, Dijkstra CD. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J Exp Med 1990;172: 1025-33.